Therefore, to help clarify this issue for clinical practice, we conducted this hospital-based cohort study to compare the OS and PFS outcomes for afatinib, erlotinib, and gefitinib as the first-line treatment in patients with EGFR mutation-positive NSCLC. This evidence concerns the gene EGFR and non-small cell lung carcinoma.